



Fig. S1. Study flow chart. ^aPatients ≥ 18 years ≥ 2 outpatient psoriasis diagnoses in the period 2001 to 2016. At least one of the diagnoses needed to be made by a dermatologist. All patients had to live in Sweden from the start of the Swedish drug prescription registry (i.e. July 2005) to the index dates. The index date was in the period 2010 to 2016. ^bPatients with a first cSCC in the period 2010 to 2016. Prior to the cSCC diagnosis, the cases needed to be cancer-free, with the exception of basal cell carcinoma (BCC). ^cThe controls needed to be alive and cancer-free (with the exception of BCC) on the index date. The matching criteria were age (same birth year) and sex. The controls were drawn from the group of eligible patients using risk set sampling. cSCC: cutaneous squamous cell carcinoma including squamous cell carcinoma *in situ*; MTX: methotrexate.